Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Moves Ahead With High-Concentration Adalimumab In Europe

Approval For Humira Rival’s 100mg/ml Formulation Follows FDA Nod Last Month

Executive Summary

Sandoz has received a formal European approval for its high-concentration Hyrimoz biosimilar rival to Humira, setting the stage for it to enter a market that also includes versions from Alvotech/Stada and Celltrion.

You may also be interested in...

Sandoz Mulls At-Risk Launch For US Natalizumab

As part of a wide-ranging discussion of its biosimilars business as it reported nine-month results, Sandoz has revealed that it is considering launching its Tysabri (natalizumab) biosimilar Tyruko “at risk” in the US, while also providing an update on its progress with adalimumab as well as certain key pipeline assets.

Novartis Hikes Sandoz Sales Guide As Separation Edges Closer

Novartis reported 8% top-line growth for its Sandoz unit during the first quarter of 2023, one of the last before it is separated into a standalone company.

Sandoz Chief Looks To Build On Recent Deals

With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts